Patent 10105421 was granted and assigned to Merz Pharma on October, 2018 by the United States Patent and Trademark Office.
The present invention pertains to pharmaceutical compositions which comprise botulinum toxin from Clostridium botulinum. The pharmaceutical compositions of the instant invention are not only free of a mammalian derived proteinaceous stabilizing agent but are free of any stabilizing protein.